Clinical Study Double-Blind Randomized Placebo Controlled

Total Page:16

File Type:pdf, Size:1020Kb

Clinical Study Double-Blind Randomized Placebo Controlled Hindawi Cholesterol Volume 2018, Article ID 4857473, 9 pages https://doi.org/10.1155/2018/4857473 Clinical Study Double-Blind Randomized Placebo Controlled Trial Demonstrating Serum Cholesterol Lowering Efficacy of a Smoothie Drink with Added Plant Stanol Esters in an Indonesian Population Lanny Lestiani,1 Dian Novita Chandra ,1 Kirsi Laitinen ,2 Fransisca Diah Ambarwati,3 Päivi Kuusisto ,4 and Widjaja Lukito 5 1 Department of Nutrition, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo General Hospital, Jakarta, Indonesia 2Institute of Biomedicine, University of Turku, 20014 Turku, Finland 3Sanghiang Perkasa-Kalbe Nutritionals, Jakarta, Indonesia 4Raisio Group, P.O. Box 101, 21201 Raisio, Finland 5Human Nutrition Research Center, Indonesian Medical Education and Research Institute, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia Correspondence should be addressed to Paivi¨ Kuusisto; [email protected] Received 25 August 2017; Accepted 1 January 2018; Published 4 February 2018 Academic Editor: Katherine Gottschall-Pass Copyright © 2018 Lanny Lestiani et al. Tis is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Indonesians have a high intake of saturated fats, a key contributing dietary factor to elevated blood cholesterol concentrations. We investigated the cholesterol lowering efcacy of a smoothie drink with 2 grams of plant stanols as esters to lower serum total and LDL-cholesterol concentrations in hypercholesterolemic Indonesian adults. Te double-blind randomized placebo controlled parallel design study involved 99 subjects. Fify subjects received control drink and dietary advice, and 49 subjects received intervention drink (Nutrive Benecol5) and dietary advice. Baseline, midline (week 2), and endline (week 4) assessments were undertaken for clinical, anthropometric, and biochemical variables. Compared to control, the smoothie drink with plant stanols reduced serum LDL-cholesterol concentration by 7.6% (� < 0.05) and 9.0% (� < 0.05)intwoandfourweeks,respectively.Serum total cholesterol was reduced by 5.7% (� < 0.05 compared to control) in two weeks, and no further reduction was detected afer four weeks (5.6%). Compared to baseline habitual diet, LDL-cholesterol was reduced by 9.3% (� < 0.05) and 9.8% (� < 0.05)inthe plant stanol ester group in two and four weeks, respectively. We conclude that consumption of smoothie drink with added plant stanol esters efectively reduces serum total and LDL-cholesterol of hypercholesterolemic Indonesian subjects already in two weeks. TrialisregisteredasNCT02316808. 1. Introduction indicates that the cardiovascular diseases are already the leading cause of death in Indonesia, accounting for 37% Similarly to other countries in Asia-Pacifc region, the of all mortality [3]. In Indonesia the major risk factors for prevalence of cardiovascular disease in Indonesia is rising cardiovascular diseases are elevated blood pressure, elevated [1]. Data from the Indonesian National Household Survey blood cholesterol, and cigarette smoking [1]. Prevalence of showed that the cause of death from noncommunicable elevated (>200 mg/dl) total cholesterol is estimated to be 40% diseases increased from 25 percent in 1980 to 49 percent in women and 30% in men [1]. Ideally, strategies to reduce in 2001 [2]. In a similar pattern, the proportion of deaths the incidence of cardiovascular diseases should be targeted arising from cardiovascular diseases in 2001 (26%) tripled at primary prevention, especially through dietary habits [4]. since 1986 (9%) [2] and has continued to rise. Recent data Furthermore, healthy dietary practices contribute to reduced 2 Cholesterol Table 1: Schedule of assessments. Week −2 (screening) 0 2 4 Informed consent X Medical history X Physical examination XX X Anthropometric measurement XX X Biochemical tests XXXX Healthy diet advice X Adverse events XX Concurrent medications XX Monitoring through phone calls XX Compliance assessment XX morbidity and mortality rates also for secondary prevention to adhere to the study conditions. Pregnant women, obese 2 [5]. (BMI > 30 kg/m ), diabetic subjects or subjects with random Initial maneuvers to manage dyslipidemia should be plasma glucose concentration >200 mg/dL, subjects with throughadietaryapproachwithaparticularfocuson hyperthyroidism, a history of metabolic, endocrine and kid- improving the quality of ingested dietary fat [6]. Terapeutic ney disorders, and acute or chronic severe diseases possibly lifestyle changes are however ofen considered burdensome interfering with the evaluation of the outcome of the clinical and call for easily applicable means for dietary modifcation trial (such as AIDS, tumor diseases, malignant hypertension, [7]. Te development of functional foods, with specifc func- and cardiac insufciency according to NYHA III-IV), and tional properties additive to normal nutritional value, should subjects who were taking lipid lowering medication or other be pursued. Plant stanols incorporated in foods as esters medications likely to afect lipid metabolism were excluded represent an important functional food substance with lipid from the study. lowering properties. Vigorous scientifc evidence pertaining Prior to commencement of the screening, the study was the total and LDL-cholesterol lowering properties of plant explained to each subject and a written informed consent stanol esters has led to their adoption as a target for lipid was signed. Te study protocol was approved by the Medical lowering modalities by several international bodies [8]. Ethics Committee of the Faculty of Medicine, Universitas While many studies demonstrating the lipid lowering Indonesia, Jakarta, Indonesia. Te study conforms to the efects of plant stanol esters have been carried out on provisions of the Declaration of Helsinki in 1995, as revised Caucasian subjects [9], the evidence is scarce for non- in Edinburgh in 2000. Caucasians, including Asians, and needs to be confrmed A total of 156 subjects indicated their interest to par- due to potential cultural diferences—through diferent food ticipateinthestudy.Teywereinvitedtovisittheclinic habits and practices. Te mainstream Indonesians are known for screening of the eligibility. Figure 1 depicts the study as a population with a high intake of saturated fats [10, 11], the fow. 99 subjects who met the entry criteria at screening key contributory dietary component to high total cholesterol were randomly allocated in a double-blind manner to receive and LDL-cholesterol concentrations [7, 12]. Terefore, the either control (�=50)orplantstanolester(�=49) present study aimed to demonstrate the lipid lowering efects smoothie drinks. Simple randomization was used. Tree of plant stanol esters in an Indonesian population. subjects in the control group and fve subjects in the plant stanol ester group discontinued the study. Of the subjects 2. Materials and Methods whocompletedtheintervention,twointhecontrolgroupand one in the plant stanol ester group were excluded from the 2.1. Study Design and Subjects. Tis double-blind random- statistical analyses because of triglyceride levels >400 mg/dl ized controlled parallel design study was conducted at the at one or several sampling points, making LDL-cholesterol Department of Nutrition, Faculty of Medicine, University determination by Friedewald formula inappropriate [13]. An of Indonesia. Te study involved 99 subjects (44 male and overall of 88 subjects were included in the statistical analyses. 55 female), aged 24–68 (mean age 47) years, who met the Te study included four visits to the study clinic, includ- following entry criteria: total cholesterol concentration ≥ ingascreeningvisit.Table1summarizestheoverallproce- 200 mg/dL and <300 mg/dL and/or LDL-C concentration ≥ dures undertaken on each subject at screening (week −2), 130 mg/dL and <240 mg/dL, willingness to consume control baseline (week 0), midline (week 2), and endline (week 4) or plant stanol ester smoothie drinks two bottles per day phases.Clinicvisitswithinanintervaloftwodaysbeforeor immediately afer a meal for four weeks, being reachable afer the appointment date were tolerated. by phone, and willingness to declare written informed consent, and agreement in accordance with data protective 2.2. Clinical Examination. General physical examination was stipulations and readiness to participate in the trial and undertaken to obtain information on vital signs and to Cholesterol 3 156 subjects agreed to give informed consent and visited the clinic 2 subjects were unable to come to the clinic 154 subjects were assessed for eligibility at screening 53 subjects were not eligible due to 2 (i) "-) > 30 EA/G (ii) Diabetes (iii) Liver dysfunction (iv) Hyperthyroidism (v) 4# < 200 GA/>,, LDL-C < 130 GA/>, (vi) 4# > 300 GA/>, 2 subjects were eligible, but not able to come for further visit 99 subjects were randomly assigned 50 subjects were allocated to 49 subjects were allocated to receive control drink receive Nutrive BenecoF drink (control group) (Benecol group) 6 subjects were discontinued 5 subjects were discontinued prematurely from the study due to prematurely from the study due to (i) Entry violation (i) Adverse event/intercurrent illnesses (ii) Adverse event/intercurrent illnesses (ii) Did not cooperate (iii) Other protocol violations (iii) Failure to return for follow-up (iv) 4' > 400 GA/>F (iv) Other protocol violations
Recommended publications
  • Acute Effects of Plant Stanol Esters on Postprandial Metabolism and Its Relation with Changes in Serum Lipids After Chronic Intake
    European Journal of Clinical Nutrition (2015) 69, 127–133 © 2015 Macmillan Publishers Limited All rights reserved 0954-3007/15 www.nature.com/ejcn ORIGINAL ARTICLE Acute effects of plant stanol esters on postprandial metabolism and its relation with changes in serum lipids after chronic intake E De Smet1, RP Mensink1, D Lütjohann2 and J Plat1 BACKGROUND/OBJECTIVES: Plant stanol esters lower serum low-density lipoprotein (LDL)-cholesterol (LDL-C), but responses between individuals vary widely. As the ability of subjects to respond to acute dietary challenges may reflect the flexibility to adapt to changes on the longer term, we related subjects' acute postprandial metabolic changes to changes in serum lipoproteins after chronic intake of plant stanol esters. SUBJECTS/METHODS: In a double-blind crossover design, 20 healthy subjects received in random order a high-fat shake enriched with or without plant stanol esters (4 g). Blood samples were taken during 4 h to examine lipid, glucose and lipoprotein profiles. Two subjects dropped out. For the 3 weeks after this postprandial test, the subjects who received the shake with plant stanol esters continued the consumption of plant stanol-enriched (3g/day) margarine and subjects receiving the control shake in the postprandial test consumed for the next 3 weeks a control margarine. After the washout period, subjects received the other shake and margarines. RESULTS: The margarine enriched with plant stanol esters lowered concentrations of total cholesterol by 7.3% (Po0.01), LDL-C by 9.5% (Po0.01) and apoB100 by 8.6% (Po0.01). Furthermore, particle concentrations of total very low-density lipoprotein (VLDL), small VLDL and large LDL were reduced by 26.6% (P = 0.02), 27.6% (P = 0.02) and 12.3% (P = 0.04), respectively.
    [Show full text]
  • Clinical Study Cholesterol Lowering Effect of Plant Stanol Ester Yoghurt Drinks with Added Camelina Oil
    Hindawi Publishing Corporation Cholesterol Volume 2016, Article ID 5349389, 12 pages http://dx.doi.org/10.1155/2016/5349389 Clinical Study Cholesterol Lowering Effect of Plant Stanol Ester Yoghurt Drinks with Added Camelina Oil Pia Salo1 and Päivi Kuusisto2 1 Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Kiinamyllynkatu 10, 20520Turku,Finland 2Raisio Nutrition Ltd., P.O. Box 101, 21201 Raisio, Finland Correspondence should be addressed to Paivi¨ Kuusisto; [email protected] Received 12 December 2015; Accepted 17 January 2016 Academic Editor: Gerhard M. Kostner Copyright © 2016 P. Salo and P. Kuusisto. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The aim of this study was to investigate the effects of yoghurt minidrinks containing two doses of plant stanol ester either with or without added camelina oil on the serum cholesterol levels in moderately hypercholesterolemic subjects. In this randomised, double-blind, parallel group study, 143 subjects consumed a 65 mL minidrink together with a meal daily for four weeks. The minidrink contained 1.6 or 2.0 grams of plant stanols with or without 2 grams of alpha-linolenic acid-rich camelina oil. The placebo minidrink did not contain plant stanols or camelina oil. All plant stanol treated groups showed statistically significant total, LDL, and non-HDL cholesterol lowering relative to baseline and relative to placebo. Compared to placebo, LDL cholesterol was lowered by 9.4% ( < 0.01) and 8.1% ( < 0.01) with 1.6 g and 2 g plant stanols, respectively.
    [Show full text]
  • PHYTOSTEROLS, PHYTOSTANOLS and THEIR ESTERS Chemical and Technical Assessment
    PHYTOSTEROLS, PHYTOSTANOLS AND THEIR ESTERS Chemical and Technical Assessment 1 Prepared by Richard Cantrill, Ph.D., reviewed by Yoko Kawamura, Ph.D., for the 69th JECFA 1. Summary Phytosterols and phytostanols, also referred to as plant sterols and stanols, are common plant and vegetable constituents and are therefore normal constituents of the human diet. They are structurally related to cholesterol, but differ from cholesterol in the structure of the side chain. Commercially, phytosterols are isolated from vegetable oils, such as soybean oil, rapeseed (canola) oil, sunflower oil or corn oil, or from so-called "tall oil", a by-product of the manufacture of wood pulp. These sterols can be hydrogenated to obtain phytostanols. Both phytosterols- and stanols, which are high melting powders, can be esterified with fatty acids of vegetable (oil) origin. The resulting esters are liquid or semi-liquid materials, having comparable chemical and physical properties to edible fats and oils, enabling supplementation of various processed foods with phytosterol- and phytostanol esters. The most common phytosterols and phytostanols are sitosterol (3β-stigmast-5-en-3ol; CAS Number 83- 46-5), sitostanol (3β,5α-stigmastan-3-ol; CAS Number 83-45-4), campesterol (3β-ergost-5-en-3-ol; CAS Number 474-62-4), campestanol (3β,5α-ergostan-3-ol; CAS Number 474-60-2), stigmasterol (3β- stigmasta-5,22-dien-3-ol; CAS Number 83-48-7) and brassicasterol (3β-ergosta-5,22-dien-3-ol; CAS Number 474-67-9). Each commercial source has its own typical composition. Dietary intake of phytosterols ranges from 150-400 mg /day in a typical western diet.
    [Show full text]
  • Dose-Dependent LDL-Cholesterol Lowering Effect by Plant Stanol Ester Consumption: Clinical Evidence Kirsi Laitinen1* and Helena Gylling2,3
    Laitinen and Gylling Lipids in Health and Disease 2012, 11:140 http://www.lipidworld.com/content/11/1/140 REVIEW Open Access Dose-dependent LDL-cholesterol lowering effect by plant stanol ester consumption: clinical evidence Kirsi Laitinen1* and Helena Gylling2,3 Abstract Elevated serum lipids are linked to cardiovascular diseases calling for effective therapeutic means to reduce particularly LDL-cholesterol (LDL-C) levels. Plant stanols reduce levels of LDL-C by partly blocking cholesterol absorption. Accordingly the consumption of foods with added plant stanols, typically esterified with vegetable oil fatty acids in commercial food products, are recommended for lowering serum cholesterol levels. A daily intake of 1.5 to 2.4 g of plant stanols has been scientifically evaluated to lower LDL-C by 7 to 10% in different populations, ages and with different diseases. Based on earlier studies, a general understanding is that no further reduction may be achieved in intakes in excess of approximately 2.5 g/day. Recent studies however suggest that plant stanols show a continuous dose–response effect in serum LDL-C lowering. This review discusses the evidence for a dose-effect relationship between plant stanol ester consumption and reduction of LDL-C concentrations with daily intakes of plant stanols of 4 g/day or more. We identified five such studies and the overall data demonstrate a linear dose-effect relationship with the most pertinent LDL-Cholesterol lowering outcome, 18%, achieved by a daily intake of 9 to 10 g of plant stanols. Along with reduction in LDL-C, the studies demonstrated a decrease in cholesterol absorption markers, the serum plant sterol to cholesterol ratios, by increasing the dose of plant stanol intake.
    [Show full text]
  • Stanol Ester Composition Stanolester Enthaltende Zusammensetzung Composition Contenant Un Ester De Stanol
    Europäisches Patentamt *EP000897971B1* (19) European Patent Office Office européen des brevets (11) EP 0 897 971 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.7: C11C 3/12, A23D 9/013, of the grant of the patent: A23D 7/00, C07J 9/00 03.11.2004 Bulletin 2004/45 (21) Application number: 98202586.8 (22) Date of filing: 31.07.1998 (54) Stanol ester composition Stanolester enthaltende Zusammensetzung Composition contenant un ester de stanol (84) Designated Contracting States: • Lievense, Lourus Cornelis BE DE DK ES FI FR GB IE IT NL SE 13270 - 000 Valinhos/SP (BR) (30) Priority: 22.08.1997 EP 97202596 (74) Representative: Van Velzen, Maaike Mathilde et al Unilever N.V., (43) Date of publication of application: Patent Department, 24.02.1999 Bulletin 1999/08 Olivier van Noortlaan 120 3133 AT Vlaardingen (NL) (73) Proprietors: • UNILEVER N.V. (56) References cited: 3000 DK Rotterdam (NL) WO-A-98/01126 WO-A-98/06405 Designated Contracting States: WO-A-98/19556 GB-A- 1 405 346 BE DE DK ES FI FR NL SE US-A- 5 502 045 • UNILEVER PLC London EC4P 4BQ (GB) • PATENT ABSTRACTS OF JAPAN vol. 011, no. Designated Contracting States: 251 (C-440), 14 August 1987 & JP 62 055040 A GB IE (NISSHIN OIL MILLS LTD:THE), 10 March 1987 (72) Inventors: • van Amerongen, Marnix P. 3133 AT Vlaardingen (NL) Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted.
    [Show full text]
  • Plant Stanol Ester Studies January 2017
    Reference list 1 (10) Plant stanol ester studies January 2017 This document includes references to all published clinical efficacy studies done with plant stanol ester. Scientific articles listed in bullet points are papers that report supplemental data from the same clinical study as the numbered article above them. A link to a full text is provided if available. Otherwise, a link to an abstract is provided. Articles that are not available online are marked accordingly. Clinical efficacy studies (in alphabetical order): 1. Algorta Pineda J, Chinchetru MJ, Aguirre J, Francisco S. [Hypocholesteremic effectiveness of a yogurt containing plant stanol esters]. In Spanish. Rev Clin Esp 2005; 205: 63-66. Link to abstract: http://www.ncbi.nlm.nih.gov/pubmed/15766477 2. Alhassan S, Reese KA, Mahurin J, Plaisance EP, Hilson BD, Garner JC, Wee SO, Grandjean PW. Blood lipid responses to plant stanol ester supplementation and aerobic exercise training. Metabolism 2006; 55: 541- 549. Link to abstract: http://www.ncbi.nlm.nih.gov/pubmed/16546486 3. Andersson A, Karlstrom B, Mohsen R, Vessby B. Cholesterol-lowering effects of a stanol ester-containing low- fat margarine used in conjunction with a strict lipid-lowering diet. Eur Heart J Suppl 1999; 1: S80-S90. Not available online. 4. Athyros VG, Kakafika AI, Papageorgiou AA, Tziomalos K, Peletidou A, Vosikis C, Karagiannis A, Mikhailidis DP. Effect of a plant stanol ester-containing spread, placebo spread, or Mediterranean diet on estimated cardiovascular risk and lipid, inflammatory and haemostatic factors. Nutr Metab Cardiovasc Dis 2011; 21: 213-221. Link to abstract: http://www.ncbi.nlm.nih.gov/pubmed/19939653 5.
    [Show full text]
  • Comparison of the Effects of Plant Sterol Ester and Plant Stanol
    European Journal of Clinical Nutrition (2000) 54, 715±725 ß 2000 Macmillan Publishers Ltd All rights reserved 0954±3007/00 $15.00 www.nature.com/ejcn Comparison of the effects of plant sterol ester and plant stanol ester-enriched margarines in lowering serum cholesterol concentrations in hypercholesterolaemic subjects on a low-fat diet MA Hallikainen1*, ES Sarkkinen1, H Gylling2, AT ErkkilaÈ1 and MIJ Uusitupa1,3 1Department of Clinical Nutrition, University of Kuopio, Kuopio, Finland; 2Department of Medicine, University of Helsinki, Helsinki, Finland; and 3Kuopio University Hospital, Kuopio, Finland Objective: To investigate cholesterol-lowering effects of stanol ester (STAEST) and sterol ester (STEEST)- enriched margarines as part of a low-fat diet. Design: According to a Latin square model randomized double-blind repeated measures design with three test margarines and three periods. Setting: Outpatient clinical trial with free-living subjects. Subjects: Thirty-four hypercholesterolaemic subjects completed the study. Interventions: Subjects consumed three rapeseed oil-based test margarines (STAEST, STEEST and control (no added stanols or sterols)) as part of a low-fat diet each for 4 weeks. Results: Mean daily intake of total plant sterols plus stanols was 2.01 ± 2.04 g during the two test margarine periods. In reference to control, serum total cholesterol was reduced by 9.2 and 7.3% with the STAEST and STEEST margarine, respectively (P<0.001 for both). The respective reductions for low-density lipoprotein (LDL) cholesterol were 12.7 and 10.4% (P<0.001). The cholesterol-lowering effects of the test margarines did not differ signi®cantly. The presence of apolipoprotein E4 allele had a signi®cant effect on LDL cholesterol response during the STAEST margarine only.
    [Show full text]
  • A Review of Plant Sterol Metabolism and Implications of Childhood Supplementation
    International Journal of Molecular Sciences Review Cardiovascular Disease Prevention: The Earlier the Better? A Review of Plant Sterol Metabolism and Implications of Childhood Supplementation Bianca Scolaro, Leticia F.S. de Andrade and Inar A. Castro * Department of Food and Experimental Nutrition, Faculty of Pharmaceutical Sciences, University of São Paulo, 05508-000 São Paulo, Brazil; [email protected] (B.S.); [email protected] (L.F.S.d.A.) * Correspondence: [email protected]; Tel.: +55-11-3091-1481 Received: 28 July 2019; Accepted: 24 August 2019; Published: 24 December 2019 Abstract: Atherosclerosis is the underlying cause of major cardiovascular events. The development of atherosclerotic plaques begins early in life, indicating that dietary interventions in childhood might be more effective at preventing cardiovascular disease (CVD) than treating established CVD in adulthood. Although plant sterols are considered safe and consistently effective in lowering plasma cholesterol, the health effects of early-life supplementation are unclear. Studies suggest there is an age-dependent effect on plant sterol metabolism: at a younger age, plant sterol absorption might be increased, while esterification and elimination might be decreased. Worryingly, the introduction of low-cholesterol diets in childhood may unintentionally favor a higher intake of plant sterols. Although CVD prevention should start as early as possible, more studies are needed to better elucidate the long-term effects of plant sterol accumulation and its implication on child development. Keywords: Atherosclerosis; plant sterol; cholesterol-lowering; diet 1. Introduction Childhood nutrition is known to play a major role in the onset of chronic diseases later in life. A large body of evidence has convincingly shown that childhood obesity is correlated with risk factors for cardiovascular disease (CVD), metabolic syndrome, and early development of atherosclerosis in adulthood.
    [Show full text]
  • Phytosterol/Stanol Enriched Foods
    Summary of evidence Phytosterol/Stanol enriched foods Updated December 2009 1300 36 27 87 www.heartfoundation.org.au Updated December 2009 PRO-095 Contents Important findings…………………………………………………………………………...5 Background information……………………………………………………………………6 NHMRC levels of evidence for clinical interventions………………………………..13 References……………………………………………………………………………………14 2 © 2007–2009 National Heart Foundation of Australia PRO-095 Summary of evidence | Phytosterol/Stanol enriched foods 3 PRO-095 This summary of evidence statement was prepared by Tuesday Udell, Nutrition Policy Coordinator, Heart Foundation, and Barbara Eden, Executive Officer, National Nutrition Program, Heart Foundation. It is based on a previous Heart Foundation nutrition policy paper, Plant sterols and stanols. A position statement from the National Heart Foundation of Australia’s Nutrition and Metabolism Advisory Committee (2003), prepared by Dr Manny Noakes. This summary of evidence was developed through a review and consultation process. A working group consisting of the following members guided the development: • Associate Professor Manny Noakes (Research Scientist, Health Sciences and Nutrition, CSIRO) • Professor David Sullivan (Clinical Lipidologist, Royal Prince Alfred Hospital) • Professor Paul Nestel (Baker Heart Research Institute) • Associate Professor Leonard Kritharides (Director of Cardiology at Concord Repatriation General Hospital). Expert comments on this summary of evidence were received from Dr Andrew Boyden (Medical Affairs Manager, Heart Foundation).
    [Show full text]
  • Plant Sterols: Factors Affecting Their Efficacy and Safety As Functional Food Ingredients Alvin Berger1, Peter JH Jones*2 and Suhad S Abumweis2
    Lipids in Health and Disease BioMed Central Review Open Access Plant sterols: factors affecting their efficacy and safety as functional food ingredients Alvin Berger1, Peter JH Jones*2 and Suhad S Abumweis2 Address: 1Head, Biochemical Profiling, Paradigm Genetics, P.O. Box 14528, Research Triangle Park, North Carolina, 27709-4528, USA and 2School of Dietetics and Human Nutrition, McGill University, 21,111 Lakeshore Road, Ste-Anne-de-Bellevue, Quebec, H9X3V9, Canada Email: Alvin Berger - [email protected]; Peter JH Jones* - [email protected]; Suhad S Abumweis - [email protected] * Corresponding author Published: 07 April 2004 Received: 13 February 2004 Accepted: 07 April 2004 Lipids in Health and Disease 2004, 3:5 This article is available from: http://www.lipidworld.com/content/3/1/5 © 2004 Berger et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL. Abstract Plant sterols are naturally occurring molecules that humanity has evolved with. Herein, we have critically evaluated recent literature pertaining to the myriad of factors affecting efficacy and safety of plant sterols in free and esterified forms. We conclude that properly solubilized 4-desmetyl plant sterols, in ester or free form, in reasonable doses (0.8–1.0 g of equivalents per day) and in various vehicles including natural sources, and as part of a healthy diet and lifestyle, are important dietary components for lowering low density lipoprotein (LDL) cholesterol and maintaining good heart health.
    [Show full text]
  • Obesity Does Not Interfere with the Cholesterol-Lowering Effect of Plant Stanol Ester Consumption (As Part of a Heart-Healthy Diet)
    Journal of Cardiovascular Development and Disease Article Obesity Does Not Interfere with the Cholesterol-Lowering Effect of Plant Stanol Ester Consumption (as Part of a Heart-Healthy Diet) Piia Simonen 1, Elisa Arte 2 and Helena Gylling 1,* 1 Heart and Lung Center, Cardiology, Helsinki University Hospital and University of Helsinki, P.O. Box 350, 00029 HUS Helsinki, Finland; piia.simonen@hus.fi 2 Raisio Nutrition Ltd., P.O. Box 101, 21201 Raisio, Finland; [email protected] * Correspondence: helena.gylling@hus.fi; Tel.: +358-50-3302402 Abstract: Dietary modifications including plant stanol ester consumption are recommended measures to control serum and low-density lipoprotein (LDL)-cholesterol concentrations, but obesity can affect their responses. We investigated whether body mass index (BMI) affects serum cholesterol levels during plant stanol (mainly sitostanol) ester consumption. This ad hoc analysis was based on earlier results of a cross-over, randomized controlled trial of postmenopausal women consuming rapeseed oil-based margarine without or with plant stanol ester (3 g plant stanols/day) for seven weeks. We classified the subjects as normal-weight (BMI ≤ 25 kg/m2, n = 9, mean 22.6 kg/m2) or overweight/obese (BMI > 25 kg/m2, n = 11, mean 28.4 kg/m2), and recalculated the results, focusing on cholesterol absorption, cholesterol synthesis, and fecal steroid outputs. Serum cholesterol levels were similar in the groups during the control diet. Plant stanol ester reduced serum cholesterol by Citation: Simonen, P.; Arte, E.; 0.63 ± 0.19 mmol/L (11%) in normal-weight and by 0.75 ± 0.13 mmol/L (12%) in overweight/obese Gylling, H.
    [Show full text]
  • Effects of Long-Term Plant Sterol Or Stanol Ester Consumption on Lipid 170.106.40.139 and Lipoprotein Metabolism in Subjects on Statin Treatment
    Downloaded from https://www.cambridge.org/core British Journal of Nutrition (2008), 100, 937–941 doi:10.1017/S0007114508966113 q The Authors 2008 Short Communication . IP address: Effects of long-term plant sterol or stanol ester consumption on lipid 170.106.40.139 and lipoprotein metabolism in subjects on statin treatment , on 1 1 2 1 Arie¨nne de Jong , Jogchum Plat , Dieter Lu¨tjohann and Ronald P. Mensink * 28 Sep 2021 at 21:19:17 1Department of Human Biology, Maastricht University, Maastricht, The Netherlands 2Institute of Clinical Chemistry and Pharmacology, University of Bonn, Bonn, Germany (Received 31 October 2007 – Revised 18 February 2008 – Accepted 21 February 2008 – First published online 1 April 2008) , subject to the Cambridge Core terms of use, available at Consumption of plant sterol- or stanol-enriched margarines by statin users results in an additional LDL-cholesterol reduction of approximately 10 %, which may be larger than the average decrease of 3–7 % achieved by doubling the statin dose. However, whether this effect persists in the long term is not known. Therefore, we examined in patients already on stable statin treatment the effects of 85 weeks of plant sterol and stanol ester consumption on the serum lipoprotein profile, cholesterol metabolism, and bile acid synthesis. For this, a double-blind randomised trial was designed in which fifty-four patients consumed a control margarine with no added plant sterols or stanols for 5 weeks (run-in period). For the next 85 weeks, seventeen subjects continued with the control margarine and the other two groups with either a plant sterol (n 18) or plant stanol (n 19) (2·5 g/d each) ester-enriched margarine.
    [Show full text]